Literature DB >> 15207074

Antibacterial resistance, Wayampis Amerindians, French Guyana.

Karine Grenet1, Didier Guillemot, Vincent Jarlier, Brigitte Moreau, Stéphane Dubourdieu, Raymond Ruimy, Laurence Armand-Lefevre, Pierre Bau, Antoine Andremont.   

Abstract

Drug resistance in fecal bacteria was high in Wayampis Amerindians who did not take antibacterial agents and were not hospitalized for 1 year. In the Wayampis Amerindians, an isolated traditional community in French Guyana, antibacterial use was 0.64 treatments per person per year. Hospitalization rate was 6.1% per year. Antibacterial drug-resistant bacteria can spread in persons who are not taking antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207074      PMCID: PMC3323165          DOI: 10.3201/eid1006.031015

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Antibacterial-resistant bacteria can spread in persons not taking antibacterial agents. This resistance results from contaminated food, antibacterial drug exposure, and cross-contamination from humans or animals. Antibacterial resistance is high in developing countries () because of self-medication, the suboptimal quality of antibacterial drugs, and poor community and patient hygiene (). To analyze the role of cross-transmission on the resistance of fecal commensal enterobacteria, we conducted a study from October 1 through 15, 2001, among Wayampis Amerindians who lived in the most southern part of French Guyana, in an isolated, ethnically homogeneous, traditional community. The community was made up of 184 males and 204 females (193 children <15 years and 195 adults), who were evenly distributed in three villages (Z, n = 248; TS, n = 85; and YP, n = 55). Access to the villages was restricted to residents, and the sites were isolated, 100 km south of the closest village. Villagers shared large huts (13.9 + 8.6 inhabitants per hut [range 4–38]) with no latrines or hygienic facilities, and used a single spot on the river for drinking, bathing, and disposal of human waste. They ate only local food (crops grown in a traditional manner and meat from fishing or hunting). They did not raise farm animals except a few free-running chickens. A paramedic officer permanently residing in Z provided the only antibacterial agents in the vicinity and recorded their dispensation. When necessary, the villagers were hospitalized in Cayenne, the capital of French Guyana. Medical care was free.

The Study

Rates of antibacterial exposure were calculated as the ratio of the number of treatments prescribed divided by the number of villagers and compared by using analysis of variance. Chi-square-tests or Fisher exact tests were used for binary variables. During the year preceding the study, 24 (6.1%) of 388 villagers had been hospitalized; 235 (60.6%) had received no treatment with antibacterial agents. One hundred fifty-three (39.4%) of the villagers had received 250 courses of antibacterial treatments. Of the therapeutic agents used, 72 (28.8%) were aminopenicillins, 111 (44.4%) were metronidazole, 36 (14.4%) were macrolides, and 31 (12.4%) were different antibacterial agents (17 penicillin M, 2 penicillin G, 7 cotrimoxazole, 3 cyclines, and 2 first-generation cephalosporins). Ninety-eight (25.3%) villagers had received one couse of treatment, 30 (7.7%) received 2 couses of treatments, 13 (3.4%) received 3 courses of treatments, and 12 (2.1%) received >4 courses of treatments. Overall antibacterial and aminopenicillin exposures were significantly higher in village Z, where the paramedical officer resided (Table 1), and in children.
Table 1

Antibacterial exposure in 388 Wayampi Amerindians from three villages in southern French Guyana during the year preceding the studya

Antibacterial agentsFrequency of antibacterial exposure in (%)
TS
(n = 85)YP
(n = 55)Z
(n = 248)Total
(N = 388)p valueb
Aminopenicillins5.914.623.818.60.007
Metronidazole16.530.932.328.60.15
Macrolides8.21.811.39.30.2
Other5.87.38.98.00.7
Overall36.554.676.264.40.007

aFrequency of antibacterial exposure was calculated by dividing the number of all antibacterial courses during the year preceding the study by the number of persons in each village.
bAnalysis of variance (ANOVA).

aFrequency of antibacterial exposure was calculated by dividing the number of all antibacterial courses during the year preceding the study by the number of persons in each village.
bAnalysis of variance (ANOVA). In October 1999, one of the investigators (V.J. or A.A.) asked each adult to participate in the study. Children were recruited with the help of the teachers at school. Exclusion criteria were fever, diarrhea, or acute infection, and a stay outside the study zone, a history of hospitalization (verified by Cayenne’s hospital records), or treatment with an antibacterial agent (verified by records of the paramedical officer) during the preceding year. We chose this period for surveillance because it was the longest period for which information was available. Information was verified by one of the investigators. The study was approved by the Comité Consultatif de Protection des Personnes se prêtant à des Recherches Biomédicales (CCPPRB) of Cayenne and by the administrative authorities of French Guyana and was authorized by the French Ministry of Health. Before participants were included, the study was presented to the villagers, with the aid of the chief of the village who explained that some of them would be asked to participate. Consent was obtained before participants were included in the study. Study participants were asked to bring fresh stool samples (unformed samples were excluded) to the paramedic officers. The samples were then mixed into brain-heart infusion broth with 10% glycerol and frozen in liquid nitrogen. Upon harvesting, 25 µL of broth was added to 2 mL of brain-heart infusion broth, incubated for 4 h, and plated on cetrimide, Chapman, and bile-esculin-acid agar containing 10 mg/L of vancomycin (after an enrichment step of 18 h in broth containing 1 mg/L of vancomycin) to detect Pseudomonas aeruginosa, Staphylococcus aureus, and vancomycin-resistant enterococci, respectively. Antibacterial-resistant gram-negative bacteria were detected by using two separate methods. The first method explored the predominant flora. Drigalski agar plates were plated with the fecal dilutions; after 48 h growth, five colonies were randomly selected, identified, and tested for antibacterial susceptibility as described (http://www.sfm.asso.fr). A participant was defined as colonized in the predominant flora with gram-negative bacteria resistant to a given antibacterial agent when at least one strain resistant to this antibacterial agent was isolated. The second method explored the subdominant flora. Drigalski agar plates were supplemented with either ampicillin (10 mg/L), ceftazidime (2 mg/L), streptomycin (20 mg/L), kanamycin (20 mg/L), chloramphenicol (20 mg/L), tetracycline (10 mg/L), or nalidixic acid (50 mg/L) (), used within 24 h after preparation, and kept at 4°C until used. The plates were plated with the fecal dilutions, incubated for 48 h, and inspected for lactose-positive and lactose-negative colonies. A participant was defined as colonized in the subdominant flora with gram-negative bacteria resistant to a given antibacterial agent when at least one colony grew on agar containing the corresponding antibacterial agent. No further identification was performed; for quality control purposes, some positive plates were randomly selected for confirmation of antibacterial susceptibility of the isolates. Because the number were few and unexpected, colonies that grew on agar containing ceftazidime were all identified by conventional methods or 16S RNA gene sequencing (), when needed; their antibacterial susceptibility was tested; and genes encoding for extended spectrum β-lactamase were characterized, when needed, by polymerase chain reaction and sequencing (). When needed, the clonality of isolates was determined by using pulsed-field gel electrophoresis (PFGE) (). The fecal flora was thus analyzed in a subgroup of 93 volunteers (39 men and 54 women; 41.2% from village TS, 18.1% from village Z, and 23.6% village YP [p < 0.001]) who met the inclusion criteria cited above, representing 93 (23.9%) of 388 villagers and 93 (39.6%) of 235 who had not received antibacterial agents for 1 year. Carriage of resistant gram-negative bacteria in subdominant flora of these 93 volunteers ranged from >90% for those resistant to ampicillin, streptomycin, and tetracycline to 7% for those resistant to nalidixic acid (Table 2), with no significant difference for sex or age. We found no association between the rate of resistance in the study participants and the number persons who used antibacterial agents or of children in the hut. Fourteen participants (all living in village Z but not in the same hut) were colonized by gram-negative bacteria resistant to ceftazidime, including three Escherichia coli strains with a similar pattern by PFGE that produced BlaTEM-52 extended spectrum β-lactamase. Nine participants (three, one, and five living in villages TS, YP and Z, respectively, and only two in the same hut) were colonized by strains of Acinetobacter baumannii sharing the same susceptibility pattern. Two participants (one in village TS and one in village Z) were colonized by strains of Ochrobactrum spp. Neither S. aureus or P. aeruginosa were isolated. One participant from village Z was colonized by a vancomycin-resistant strain of Enterococcus gallinarum.
Table 2

Prevalence of carriage of gram-negative bacteria resistant to various antibacterial agents in the predominant and the subdominant fecal flora of the 93 study participantsa

Antibacterial agentPredominant florab
Subdominant flora
Escherichia coli (%)Klebsiella sp. (%)Enterobacter sp. (%)Other (%)Any (%)Lactose positive (%)Lactose negative (%)Any (%)
Ampicillin51 (55)19 (21)5 (5)2 (2)77 (83)89 (96)31 (33)93 (100)
Ceftazidime000003c (4)11d (12)14 (15)
Nalidixic acid000007e (8)07 (8)
Pefloxacine00000NDNDND
Streptomycin42 (45)2 (2)0044 (47)83 (90)19 (21)86 (93)
Kanamycin5 (5)0005 (5)45 (49)4 (5)47 (51)
Tetracycline59 (63)14 (15)02 (2)75 (81)86 (93)25 (27)86 (93)
Cotrimoxazole27 (29)00027 (29)NDNDND
Chloramphenicol22 (24)00022 (24)48 (52)27 (29)60 (67)

aAccounting for 23.9% (93 of 388) of the global population of the villages studied and not significantly different from it for male/female ratio or age distribution.
bBacteria with intermediate susceptibility were categorized as resistant.
cExtended spectrum β-lactamase E. coli.
dAcinetobacter baumanni: 9 (all with the same susceptibility pattern including susceptibility to ureidopenicillins, third-generation cephalosporins, aminoglycosides, and quinolones) and Ochrobactrum spp. (identified by 16s RNA genes sequencing): 2.
eE. coli.

aAccounting for 23.9% (93 of 388) of the global population of the villages studied and not significantly different from it for male/female ratio or age distribution.
bBacteria with intermediate susceptibility were categorized as resistant.
cExtended spectrum β-lactamase E. coli.
dAcinetobacter baumanni: 9 (all with the same susceptibility pattern including susceptibility to ureidopenicillins, third-generation cephalosporins, aminoglycosides, and quinolones) and Ochrobactrum spp. (identified by 16s RNA genes sequencing): 2.
eE. coli. Resistance rates in the predominant flora were from 95% to tetracycline to 0% to ceftazidime and nalidixic acid, with no significant differences between adults and children, men and women, or villages. Although they were not chosen randomly, approximately 40% of the untreated villagers were included, which suggests that the group was representative of the whole community. Recently, high resistance rates were also reported in remote populations from Bolivia () and Nepal (). Here, however, we have provided additional information on exposure to antibacterial drugs and hospitalizations of the study participants. In the villages studied, the global antibacterial exposure (0.64 treatments/person/year) was roughly half that of France (), thus close to the mean rate of European Union countries (), which stresses the indirect impact of antibacterial use on persons who do not use them. Unrecorded antibacterial drug use in the participants was unlikely because no alternate sources of antibacterial agents existed, and free antibacterial agents were provided when needed, decreasing the likelihood of nonprescribed use or sharing of antibacterial agents by family members. Our results can be compared only to those of studies performed with similar methods and in persons who also had not taken antibacterial drugs. For instance, resistance rates of predominant E. coli in the Wayampis population to ampicillin, tetracycline, and streptomycin were higher than that observed in French bank workers () or Bostonian children (), but close to that reported in children from Venezuela and China (). That the resistance rate was higher in the Wayampis Amerindians than in the French workers was unexpected, considering the higher levels of antibacterial drug use in the French community. These data suggested frequent cross-transmission likely attributable to poor hygiene (,). Cross-transmission is common among households, even in industrialized countries (). Its role in the spread of drug-resistant bacteria among the Wayampis Amerindians, even in adults, was further indicated by the lack of difference in resistance rates according to age. Resistance to quinolones, which were not used in this community, was lower than in Europe (), which illustrates the specificity of selective pressure. Third-generation cephalosporins were also not used. Thus, how samples from three participants were colonized by an E. coli–carrying BlaTEM-52 (), an extended-spectrum β-lactamase-gene found only in hospitals, is difficult to explain. However, enterobacteria that produced an extended spectrum β-lactamase were prevalent at the time in the Cayenne hospital (B.M., unpub. data). Since the three persons with the BlaTEM-52 -colonized samples had not been hospitalized during the previous year, possibly this strain, or a different one, carrying BlaTEM-52 was acquired and spread in the community by one of the 24 villagers hospitalized during the year preceding the study. Extended-spectrum β-lactamase can disseminate in the community (). We cannot exclude that the three BlaTEM-52 carriers had been hospitalized earlier. If they were hospitalized and colonized during hospitalization, this colonization would not have been likely to have persisted for so long; indeed, carriage of resistant nasal staphylococci can last for months, but resistance in intestinal enterobacteria decreases within 10–20 days after selective pressure ends ().

Conclusions

Antibacterial agents in the food chain are a source of resistance in industrialized countries (). In our study, food was strictly local but may have been the source of the wild-type naturally resistant A. baumannii and Ochrobactrum spp. strains that we isolated. Environmental species have also been isolated in Amerindians living in nearby (formerly Dutch) Guyana (). Because data confirmed the lack of direct antibacterial drug exposure in our study participants, the results demonstrate that, once resistance elements are introduced into a population, moderate use of antibacterial drugs in the environment is enough to maintain them in intestinal bacteria when sanitary conditions are poor.
  16 in total

Review 1.  Antibiotic use in humans and bacterial resistance.

Authors:  D Guillemot
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

2.  Variation in antibiotic use in the European Union.

Authors:  O Cars; S Mölstad; A Melander
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

3.  Antimicrobial susceptibility of community-acquired uropathogens in northern Israel.

Authors:  R Colodner; Y Keness; B Chazan; R Raz
Journal:  Int J Antimicrob Agents       Date:  2001-08       Impact factor: 5.283

4.  Emergence and dissemination of quinolone-resistant Escherichia coli in the community.

Authors:  J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Molecular characterisation by PCR-restriction fragment length polymorphism of TEM beta-lactamases.

Authors:  G Arlet; G Brami; D Décrè; A Flippo; O Gaillot; P H Lagrange; A Philippon
Journal:  FEMS Microbiol Lett       Date:  1995-12-15       Impact factor: 2.742

6.  Shedding of antibiotic-resistant members of the family Enterobacteriaceae in healthy residents of France and Jordan.

Authors:  E Chachaty; M T Youssef; C Bourneix; A Andremont
Journal:  Res Microbiol       Date:  1995-02       Impact factor: 3.992

7.  Trimethoprim-resistant Escherichia coli in households of children attending day care centers.

Authors:  M Fornasini; R R Reves; B E Murray; A L Morrow; L K Pickering
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

8.  A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae.

Authors:  C Poyart; P Mugnier; G Quesne; P Berche; P Trieu-Cuot
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

9.  Patterns of antimicrobial use and antimicrobial resistance among healthy children in Bolivia.

Authors:  A Bartoloni; F Cutts; S Leoni; C C Austin; A Mantella; P Guglielmetti; M Roselli; E Salazar; F Paradisi
Journal:  Trop Med Int Health       Date:  1998-02       Impact factor: 2.622

10.  DNA fingerprinting of Escherichia coli O157:H7 strains by pulsed-field gel electrophoresis.

Authors:  H Böhm; H Karch
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

View more
  23 in total

1.  Evolution of nasal carriage of methicillin-resistant coagulase-negative staphylococci in a remote population.

Authors:  David Lebeaux; François Barbier; Cécile Angebault; Lahcene Benmahdi; Etienne Ruppé; Benjamin Felix; Kevin Gaillard; Félix Djossou; Loïc Epelboin; Claire Dupont; Magaly Renard; Gilles Peroz; François Vandenesch; Michel Wolff; Antoine Andremont; Raymond Ruimy
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Carriage of Enterobacteria Producing Extended-Spectrum β-Lactamases and Composition of the Gut Microbiota in an Amerindian Community.

Authors:  María José Gosalbes; Jorge F Vázquez-Castellanos; Cécile Angebault; Paul-Louis Woerther; Etienne Ruppé; María Loreto Ferrús; Amparo Latorre; Antoine Andremont; Andrés Moya
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

3.  Population structure and resistance genes in antibiotic-resistant bacteria from a remote community with minimal antibiotic exposure.

Authors:  Lucia Pallecchi; Chiara Lucchetti; Alessandro Bartoloni; Filippo Bartalesi; Antonia Mantella; Herlan Gamboa; Alessandra Carattoli; Franco Paradisi; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Discovery of 1,4-dihydroxy-2-naphthoate [corrected] prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens.

Authors:  Michio Kurosu; Prabagaran Narayanasamy; Kallolmay Biswas; Rakesh Dhiman; Dean C Crick
Journal:  J Med Chem       Date:  2007-07-21       Impact factor: 7.446

5.  Carriage of CTX-M-15-producing Escherichia coli isolates among children living in a remote village in Senegal.

Authors:  Etienne Ruppé; Paul-Louis Woerther; Abdoulaye Diop; Anne-Marie Sene; Annaelle Da Costa; Guillaume Arlet; Antoine Andremont; Bernard Rouveix
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  Characterization of fecal extended-spectrum-β-lactamase-producing Escherichia coli in a remote community during a long time period.

Authors:  Paul-Louis Woerther; Cécile Angebault; Hervé Jacquier; Olivier Clermont; Assyia El Mniai; Brigitte Moreau; Félix Djossou; Gilles Peroz; François Catzeflis; Erick Denamur; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

7.  Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.

Authors:  Joy Debnath; Shajila Siricilla; Bajoie Wan; Dean C Crick; Anne J Lenaerts; Scott G Franzblau; Michio Kurosu
Journal:  J Med Chem       Date:  2012-04-06       Impact factor: 7.446

8.  Improved synthesis of capuramycin and its analogues.

Authors:  Yong Wang; Shajila Siricilla; Bilal A Aleiwi; Michio Kurosu
Journal:  Chemistry       Date:  2013-09-06       Impact factor: 5.236

9.  Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymycins.

Authors:  Bilal A Aleiwi; Christopher M Schneider; Michio Kurosu
Journal:  J Org Chem       Date:  2012-04-06       Impact factor: 4.354

10.  Real-time PCR for quantitative analysis of human commensal Escherichia coli populations reveals a high frequency of subdominant phylogroups.

Authors:  Mounira Smati; Olivier Clermont; Frédéric Le Gal; Olivier Schichmanoff; Françoise Jauréguy; Alain Eddi; Erick Denamur; Bertrand Picard
Journal:  Appl Environ Microbiol       Date:  2013-06-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.